A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 4023393A (Primary) ; DTaP vaccine; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate
Indications Meningococcal infections
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

Most Recent Events

24 May 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
21 Mar 2024 This trial has been completed in Sweden according to European Clinical Trials Database record
08 Mar 2024 Planned End Date changed from 19 Jan 2024 to 30 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight